https://www.selleckchem.com/products/6-diazo-5-oxo-l-norleucine.html 9 [197.7] days vs 72.7 [188.0] days; = .001). However, statin use was not associated with SSNHL after adjusting for the confounders (adjusted OR, 1.04; 95% CI, 0.98-1.11; = .245). There was a positive correlation between statin use and SSNHL in the crude model (crude OR, 1.10; 95% CI, 1.04-1.16; = .001). However, there was no association between statin use and SSNHL in all subgroup analyses. Previous statin use was not associated with SSNHL. Previous statin use was not associated with SSNHL. To comprehensively investigate nasopharyngeal carcinoma (NPC) treatment, overall survival (OS), and the influence of clinical/sociodemographic factors on outcome. Retrospective database study. National Cancer Database. The 2004-2015 National Cancer Database was queried for all patients with NPC receiving definitive treatment. Log-rank tests and Cox proportional hazards models were used for statistical analyses. A total of 8260 patients with NPC were included (71.4% male; 42.5% with keratinizing histology; mean ± SD age, 52.1 ± 15.1 years), with a 5-year OS of 63.4%. Multivariate predictors of mortality included age ≥65 years (hazard ratio [HR], 1.81; < .001), Charlson/Deyo score ≥1 (HR, 1.27; = .001), American Joint Committee on Cancer clinical stage III to IV (HR, 1.85; < .001), and government insurance or no insurance (HR, 1.53; < .001). Predictors of survival included female sex (HR, 0.82; = .002), Asian/Pacific Islander race (HR, 0.74; < .001), nonkeratinizing/undifnt on a variety of clinical/sociodemographic factors. Stage-specific treatments with optimal OS include CRT or RT for stages I to II and CRT for stage III to IV. The large representation of nonendemic histology is valuable, as these cases are not well characterized.Thus far, there are more than known 150 modifications to RNA, in which common internal modifications of mRNA include N6-methyladenosine (m6A), N1-methyladenosine, and 5-methylcytosine.